bronchial asthma
Conditions
Interventions
Trade Name: EFIENT
Pharmaceutical Form: Coated tablet
Concentration unit: mg milligram(s)
Concentration number: 10-
Pharmaceutical form of the placebo: Coated tablet
Route of administration of the pla
Sponsors
AZIENDA OSPEDALIERA S. PAOLO (A.O. DI RILIEVO NAZIONALE)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Allergic asthma patients diagnosed with non-smokers defined Are the trial subjects under 18? no Number of subjects for this age range: 0 F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: 1 - Pregnancy / breast-feeding, 2 - bleeding or high risk of bleeding 3 - Eta '> = 75 years 4 - Previous TIA or ischemic stroke, 5 - Other information antiagrregante platelet therapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: Modification of bronchial hyperresponsiveness bronchial challenge test with mannitol.;Secondary Objective: Change in concentration of inflammatory markers in sputum bronchial Changes of exhaled nitric oxide as a marker of eosinophilic airway inflammation.;Primary end point(s): Modification of bronchial hyperresponsiveness bronchial challenge test with mannitol. | — |
Countries
Italy
Outcome results
None listed